Difference between revisions of "PEDS5:Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
[checked revision] | [checked revision] |
(11 intermediate revisions by the same user not shown) | |||
Line 6: | Line 6: | ||
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | ||
+ | |||
+ | __TOC__ | ||
{| class="wikitable" style="margin:auto" | {| class="wikitable" style="margin:auto" | ||
|+<big>WHO Classification of Paediatric Tumours (5th Edition) Content</big> | |+<big>WHO Classification of Paediatric Tumours (5th Edition) Content</big> | ||
Line 16: | Line 18: | ||
!'''Date of Last Editor Review''' | !'''Date of Last Editor Review''' | ||
!'''Notes''' | !'''Notes''' | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 2 (HAEMATOLYMPHOID DISORDERS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[PEDS5:Chronic_myeloid_leukaemia_(CML)|Chronic myeloid leukaemia (CML)]] | |[[PEDS5:Chronic_myeloid_leukaemia_(CML)|Chronic myeloid leukaemia (CML)]] | ||
Line 434: | Line 457: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 3 (CNS TUMOURS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[PEDS5:Diffuse_astrocytoma,_MYB-_or_MYBL1-altered|Diffuse astrocytoma, MYB- or MYBL1-altered]] | |[[PEDS5:Diffuse_astrocytoma,_MYB-_or_MYBL1-altered|Diffuse astrocytoma, MYB- or MYBL1-altered]] | ||
Line 940: | Line 984: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 4 (PERIPHERAL NEUROBLASTIC TUMOURS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[PEDS5:Ganglioneuroma|Ganglioneuroma]] | |[[PEDS5:Ganglioneuroma|Ganglioneuroma]] | ||
Line 985: | Line 1,050: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
| | | | ||
+ | ==== CHAPTER 5 (EYE TUMOURS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | |[[PEDS5:Epibulbar_osseous_choristoma|Epibulbar osseous choristoma]] | + | |[[PEDS5:Epibulbar_choristoma|Epibulbar choristoma]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[PEDS5:Epibulbar_osseous_choristoma|Epibulbar osseous choristoma]] | ||
|Disease | |Disease | ||
| | | | ||
Line 1,105: | Line 1,191: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 6 (SOFT TISSUE AND BONE TUMOURS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[PEDS5:Lipomatosis|Lipomatosis]] | |[[PEDS5:Lipomatosis|Lipomatosis]] | ||
Line 2,172: | Line 2,279: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 7 (GERM CELL TUMOURS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[PEDS5:Intratubular_germ_cell_neoplasia_(male_gonadal)|Intratubular germ cell neoplasia (male gonadal)]] | |[[PEDS5:Intratubular_germ_cell_neoplasia_(male_gonadal)|Intratubular germ cell neoplasia (male gonadal)]] | ||
Line 2,327: | Line 2,455: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
| | | | ||
+ | ==== CHAPTER 8 (RENAL AND MALE GENITAL TUMOURS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | |[[PEDS5:Nephroblastoma|Nephroblastoma]] | + | |[[PEDS5:Paediatric_cystic_nephroma|Paediatric cystic nephroma]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[PEDS5:Nephroblastoma|Nephroblastoma]] | ||
|Disease | |Disease | ||
| | | | ||
Line 2,502: | Line 2,651: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 9 (FEMALE GENITAL TUMOURS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[PEDS5:Ovarian_fibroma|Ovarian fibroma]] | |[[PEDS5:Ovarian_fibroma|Ovarian fibroma]] | ||
Line 2,635: | Line 2,805: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
| | | | ||
+ | ==== CHAPTER 10 (BREAST TUMOURS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | |[[PEDS5: | + | |[[PEDS5:Fibroepithelial_tumours_|Fibroepithelial tumours]] |
|Disease | |Disease | ||
| | | | ||
Line 2,657: | Line 2,837: | ||
| | | | ||
|- | |- | ||
− | |[[PEDS5: | + | |[[PEDS5:Juvenile_fibroadenoma|Juvenile fibroadenoma]] |
|Disease | |Disease | ||
| | | | ||
Line 2,668: | Line 2,848: | ||
| | | | ||
|- | |- | ||
− | |[[PEDS5: | + | |[[PEDS5:Juvenile_papillomatosis|Juvenile papillomatosis]] |
|Disease | |Disease | ||
| | | | ||
Line 2,679: | Line 2,859: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
| | | | ||
+ | ==== CHAPTER 11 (DIGESTIVE SYSTEM TUMOURS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | |[[PEDS5:Paediatric_hepatocellular_carcinoma|Paediatric hepatocellular carcinoma]] | + | |[[PEDS5:Hepatoblastoma|Hepatoblastoma]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[PEDS5:Fibrolamellar_variant_of_hepatocellular_carcinoma|Fibrolamellar variant of hepatocellular carcinoma]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[PEDS5:Paediatric_hepatocellular_carcinoma|Paediatric hepatocellular carcinoma]] | ||
|Disease | |Disease | ||
| | | | ||
Line 2,821: | Line 3,033: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 12 (ENDOCRINE TUMOURS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[PEDS5:Follicular_adenoma_of_the_thyroid|Follicular adenoma of the thyroid]] | |[[PEDS5:Follicular_adenoma_of_the_thyroid|Follicular adenoma of the thyroid]] | ||
Line 2,943: | Line 3,176: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
| | | | ||
+ | ==== CHAPTER 13 (HEAD AND NECK TUMOURS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | |[[PEDS5:White_sponge_naevus|White sponge naevus]] | + | |[[PEDS5:Squamous_cell_papilloma_of_the_larynx|Squamous cell papilloma of the larynx]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[PEDS5:White_sponge_naevus|White sponge naevus]] | ||
|Disease | |Disease | ||
| | | | ||
Line 3,129: | Line 3,383: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 14 (THORACIC TUMOURS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[PEDS5:Fetal_lung_interstitial_tumour|Fetal lung interstitial tumour]] | |[[PEDS5:Fetal_lung_interstitial_tumour|Fetal lung interstitial tumour]] | ||
Line 3,173: | Line 3,448: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | | | ||
+ | ==== CHAPTER 15 (SKIN TUMOURS) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
|[[PEDS5:Hamartomas|Hamartomas]] | |[[PEDS5:Hamartomas|Hamartomas]] | ||
Line 3,284: | Line 3,580: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
| | | | ||
+ | ==== CHAPTER 16 (GENETIC TUMOUR SYNDROMES) ==== | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[PEDS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] | ||
+ | |Disease | ||
+ | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
+ | |N/A | ||
|- | |- | ||
|[[PEDS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]] | |[[PEDS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
|[[PEDS5:Tuberous_sclerosis|Tuberous sclerosis]] | |[[PEDS5:Tuberous_sclerosis|Tuberous sclerosis]] | ||
Line 3,341: | Line 3,658: | ||
|[[PEDS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]] | |[[PEDS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
|[[PEDS5:Hereditary_phaeochromocytoma-paraganglioma_syndromes|Hereditary phaeochromocytoma-paraganglioma syndromes]] | |[[PEDS5:Hereditary_phaeochromocytoma-paraganglioma_syndromes|Hereditary phaeochromocytoma-paraganglioma syndromes]] | ||
Line 3,363: | Line 3,680: | ||
|[[PEDS5:WAGR_syndrome|WAGR syndrome]] | |[[PEDS5:WAGR_syndrome|WAGR syndrome]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
|[[PEDS5:Beckwith-Wiedemann_and_related_overgrowth_syndromes|Beckwith-Wiedemann and related overgrowth syndromes]] | |[[PEDS5:Beckwith-Wiedemann_and_related_overgrowth_syndromes|Beckwith-Wiedemann and related overgrowth syndromes]] | ||
Line 3,385: | Line 3,702: | ||
|[[PEDS5:Familial_adenomatous_polyposis|Familial adenomatous polyposis]] | |[[PEDS5:Familial_adenomatous_polyposis|Familial adenomatous polyposis]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
|[[PEDS5:Lynch_syndrome|Lynch syndrome]] | |[[PEDS5:Lynch_syndrome|Lynch syndrome]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
|[[PEDS5:Xeroderma_pigmentosum|Xeroderma pigmentosum]] | |[[PEDS5:Xeroderma_pigmentosum|Xeroderma pigmentosum]] | ||
Line 3,429: | Line 3,746: | ||
|[[PEDS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] | |[[PEDS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
|[[PEDS5:DICER1_syndrome|DICER1 syndrome]] | |[[PEDS5:DICER1_syndrome|DICER1 syndrome]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
|[[PEDS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]] | |[[PEDS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]] | ||
Line 3,462: | Line 3,779: | ||
|[[PEDS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]] | |[[PEDS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
|- | |- | ||
|[[PEDS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]] | |[[PEDS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]] |
Latest revision as of 14:11, 10 September 2024
Welcome!
For assignments, please see the "Author" column below (highlighted blue).
If empty (no name is present), please volunteer to create content for that disease!
To volunteer, please [Contact us] with your page of interest.